Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better predict response. PD-L1 IHC remains a valuable tool for predicting patient...
Key takeaways Understanding the frequency and nature of immune cell clustering is useful in determining patient responses to immunomodulating therapies Flagship’s unique spatial biology services generated a validated computational pathology score that characterized...
Abstract Multiplexed analysis of limited tissue samples can improve our understanding of tumor biology and the tumor microenvironment. Chromogenic and fluorescent multiplexed immunohistochemistry (IHC) approaches are available and offer great insights while conserving...
Abstract Using immunohistochemistry (IHC) to examine immune infiltrates in tissue biopsy samples to support exploratory investigations for immuno-oncology drug development is critical for understanding the abundance and spatial relationships of different immune cell...
Key takeaways The RNAscope® platform enabled duplex chromogenic in situ hybridization (CISH) assay visualization of mRNA targets from multiple cell types and biomarkers Quantification of individual and dual cell positivity within tissue compartments Spatial biology...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Introduction and BackgroundDr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is fellowship-trained in surgical pathology...
Introduction and BackgroundAdam Beharry, PhD, is a Flagship scientist who describes his work as applying advanced technical knowledge and critical thinking to expand Flagship’s tissue image analysis in neuromuscular and rare diseases. Adam’s degrees include: BS –...
IntroductionThe success of clinical trials is highly dependent on the intricacies of patient recruitment. Other challenges, from the costs of clinical supplies to the specific procedural requirements that can extend physicians’ time, can increase costs. There are also...
EVENTS
Reuniting 100+ leading experts in biotech, pharma, and academia. February 21-23, 2023. We’re headed to Boston to join other leading experts in biotech, pharma and academia to discuss obstacles in clinical trials and strategies for delivering safer and more effective...
Join Flagship for the Oncology Companion Diagnostics Xchange at hubXchange West. February 6-9, 2023. Attending hubXchange West? Meet with us to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program....
Visit Flagship at the SB-IO Summit.January 17-19, 2023. Attending the inaugural SB-IO Summit? Stop by our booth to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program. AI-powered digital pathology solutions...